Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

doi:10.1159/000538558

Related publications

Article2020

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, Su Pin Choo, Masatoshi Kudo

Article2024

Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

Linda Y. Wu, Sarah Cappuyns, Amanda S. Loh, Sean Sun, Sara Lewis, Max W. Sung, Myron Schwartz, Josep M. Llovet, Deirdre Jill Cohen

BJC Reports

Article2022

Addition of tyrosine kinase inhibitors (TKIs) in patients (pts) with unresectable hepatocellular carcinoma (HCC) who progress on first-line immunotherapy (IO).

Linda Wu, Roger Esteban, Michelle Rudshteyn, Myron Schwartz, Max W. Sung, Josep M. Llovet, Deirdre Jill Cohen

Journal of Clinical Oncology

Article2022

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle,

Editorial Material2022

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Masatoshi Kudo